Preview

Научно-практическая ревматология

Расширенный поиск

Проблемы боли и качества жизни при ревматоидном артрите: фокус на барицитиниб

https://doi.org/10.47360/1995-4484-2020-420-427

Аннотация

Современная патогенетическая терапия ревматоидного артрита (РА) позволяет не только снижать активность иммунного воспаления и замедлять прогрессирование болезни, но и обеспечивать максимально быстрое устранение основных симптомов, вызывающих наибольшее беспокойство пациентов – боли, нарушения функции, утомляемости. Таким действием обладает ингибитор янус-киназ 1 и 2 – барицитиниб (БАРИ), который быстро снижает активность воспаления, обеспечивает достижение ремиссии при РА, обладает высоким анальгетический потенциалом. В обзоре обсуждается роль аутоиммунного воспаления и внутриклеточного сигнального пути JAK/STAT (Janus kinase/signal transducers and activators of transcription) в патогенезе хронической боли при РА, роль БАРИ как средства для эффективного контроля интенсивности боли и усталости. 

Об авторе

А. Е. Каратеев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

доктор медицинских наук, зав. лабораторией патофизиологии боли и клинического полиморфизма скелетно-мышечных заболеваний,

115522, Москва, Каширское шоссе, 34А



Список литературы

1. Smolen J, Aletaha D, Barton A, et al. Rheumatoid Arthritis. Nat Rev Dis Primers. 2018;4:18001. Published 2018 Feb 8. doi:10.1038/nrdp.2018.1

2. Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263-271. https://doi.org/10.14412/1995-4484-2018-263-271

3. Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-419. Doi:10.14412/1995-4484-2017-409-419

4. Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. J Clin Med. 2019; 8(7):938. doi: 10.3390/jcm8070938

5. Burmester G, Bijlsma J, Cutolo M, McInnes I. Managing Rheumatic and Musculoskeletal Diseases – Past, Present and Future. Nat Rev Rheumatol. 2017; 13(7):443-448. doi: 10.1038/nrrheum.2017.95

6. Van Tuyl LH, Michaud K. Patient-Reported Outcomes in Rheumatoid Arthritis. Rheum Dis Clin North Am. 2016; 42(2):219-37. doi: 10.1016/j.rdc.2016.01.010

7. Fautrel B, Alten R, Kirkham B, et al. Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int. 2018; 38(6):935-947. doi: 10.1007/s00296-018-4005-5

8. Smolen JS, Strand V, Koenig AS, Szumski A, Kotak S, Jones TV. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res Ther. 2016; 18(1):114. doi: 10.1186/s13075-016-1004-3

9. Zhang A, Lee YC. Mechanisms for Joint Pain in Rheumatoid Arthritis (RA): from Cytokines to Central Sensitization. Curr Osteoporos Rep. 2018;16(5):603-610. doi: 10.1007/s11914-018-0473-5

10. Sharma J, Bhar S, Devi CS. A review on interleukins: The key manipulators in rheumatoid arthritis. Mod Rheumatol. 2017; 27(5):723-746. doi: 10.1080/14397595.2016.1266071

11. Ge C, Holmdahl R. The structure, specificity and function of anti-citrullinated protein antibodies. Nat Rev Rheumatol. 2019;15(8):503-508. doi: 10.1038/s41584-019-0244-4

12. Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing Receptors in Sterile Inflammation and Inflammatory Diseases. Nat Rev Immunol. 2020; 20(2):95-112. doi: 10.1038/s41577-019-0215-7

13. Takeuchi Y, Hirota K, Sakaguch S. Synovial Tissue Inflammation Mediated by Autoimmune T Cells. Front Immunol. 2019;10:1989. doi: 10.3389/fimmu.2019.01989.

14. Nagata S. Apoptosis and Clearance of Apoptotic Cells. Annu Rev Immunol. 2018 Apr 26;36:489-517. doi: 10.1146/annurev-immunol-042617-053010

15. Smith Jr T, Tharakan A, Martin R. Targeting ADAM10 in Cancer and Autoimmunity. Front Immunol. 2020; 11:499. doi: 10.3389/fimmu.2020.00499

16. Deane K, Holers V. The Natural History of Rheumatoid Arthritis. Clin Ther. 2019;41(7):1256-1269. doi: 10.1016/j.clinthera.2019.04.028

17. Uciechowski P, Dempke W. Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020; 98(3):131-137. doi: 10.1159/000505099

18. Crotti C, Agape E, Becciolini A, Biggioggero M, Favalli EG. Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. Drugs. 2019; 79(16):1741-1755. doi: 10.1007/s40265-019-01192-z

19. Katz EJ, Gold MS. Inflammatory hyperalgesia: a role for the C-fiber sensory neuron cell body? J Pain. 2006; 7(3):170-8. doi: 10.1016/j.jpain.2005.10.003

20. Chen X, Alessandri-Haber N, Levine JD. Marked attenuation of inflammatory mediator-induced C-fiber sensitization for mechanical and hypotonic stimuli in TRPV4-/- mice. Mol Pain. 2007; 3:31. doi: 10.1186/1744-8069-3-31

21. Lee C-H, Giuliani F. The Role of Inflammation in Depression and Fatigue. Front Immunol. 2019 Jul 19;10:1696. doi: 10.3389/fimmu.2019.01696

22. Kim K-H, Seo H-J, Abdi S., Huh B. All About Pain Pharmacology: What Pain Physicians Should Know. Korean J Pain. 2020;33(2):108-120. doi: 10.3344/kjp.2020.33.2.108

23. Harth M, Nielson WR. Pain and affective distress in arthritis: relationship to immunity and inflammation. Expert Rev Clin Immunol. 2019; 15(5):541-552. doi: 10.1080/1744666X.2019.1573675

24. Yang S, Chang M. Chronic Pain: Structural and Functional Changes in Brain Structures and Associated Negative Affective States. Int J Mol Sci. 2019; 20(13):3130. doi: 10.3390/ijms20133130

25. Zhao SS, Duffield SJ, Goodson NJ. The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis. Best Pract Res Clin Rheumatol. 2019;33(3):101423. doi: 10.1016/j.berh.2019.06.005

26. Dougados M, Perrot S. Fibromyalgia and central sensitization in chronic inflammatory joint diseases. Joint Bone Spine. 2017; 84(5):511-513. doi: 10.1016/j.jbspin.2017.03.001

27. Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 5): v29-v34. doi: 10.1093/rheumatology/kez346

28. Daviu N, Bruchas M, Moghaddam B, Sandi C, Beyeler A. Neurobiological Links Between Stress and Anxiety. Neurobiol Stress. 2019; 11:100191. doi: 10.1016/j.ynstr.2019.100191.

29. Maloley PM, England BR, Sayles H, et al. Post-traumatic stress disorder and serum cytokine and chemokine concentrations in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019; 49(2):229-235. doi: 10.1016/j.semarthrit.2019.02.002

30. Tiosano S, Yavne Y, Watad A, et al. The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis.Eur J Clin Invest. 2020 Jun 1:e13268. doi: 10.1111/eci.13268

31. Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018;22(2):216-241. doi: 10.1002/ejp.1140

32. Kaplan C, Minc A, Basu N, Schrepf A. Inflammation and the Central Nervous System in Inflammatory Rheumatic Disease. Curr Rheumatol Rep. 2019;21(12):67. doi: 10.1007/s11926-019-0870-5

33. Kiguchi N, Kobayashi D, Saika F, Matsuzaki S, Kishioka S. Pharmacological Regulation of Neuropathic Pain Driven by Inflammatory Macrophages. Int J Mol Sci. 2017;18(11):2296. doi: 10.3390/ijms18112296

34. Siouti E, Andreakos E. The many facets of macrophages in rheumatoid arthritis. Biochem Pharmacol. 2019;165:152-169. doi: 10.1016/j.bcp.2019.03.029

35. Kothari P, Pestana R, Mesraoua R, et al. IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAKdependent IL-10 expression in macrophages. J Immunol. 2014;192(1):349-57. doi: 10.4049/jimmunol.1301906

36. Salaffi F, Giacobazzi G, Di Carlo M. Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway. Pain Res Manag. 2018;2018:8564215

37. Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуно-воспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. doi:10.14412/1995-4484-2019-8-16.

38. Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. doi: 10.1007/s40259-019-00333-w

39. Park SJ, Lee JH, Kim HY, et al. Astrocytes, but not microglia, rapidly sense H₂O₂via STAT6 phosphorylation, resulting in cyclooxygenase-2 expression and prostaglandin release. J Immunol. 2012;188(10):5132-5141. doi:10.4049/jimmunol.1101600

40. Ding CP, Guo YJ, Li HN, et al. Red nucleus interleukin-6 participates in the maintenance of neuropathic pain through JAK/ STAT3 and ERK signaling pathways. Exp Neurol. 2018 Feb;300:212-221. DOI: 10.1016/j.expneurol.2017.11.012

41. Xu Z, Wu H, Zhang H, Bai J, Zhang Z. Interleukins 6/8 and cyclooxygenase-2 Release and Expressions Are Regulated by Oxidative stress-JAK2/STAT3 Signaling Pathway in Human Bronchial Epithelial Cells Exposed to Particulate Matter ≤2.5 μm. J Appl Toxicol. 2020 Mar 24. doi: 10.1002/jat.3977

42. Choy EHS, Miceli-Richard C, González-Gay MA, et al. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clin Exp Rheumatol. 2019;37(4):694- 704

43. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655

44. Насонов ЕЛ, Лила АМ. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2020;58(3):304-316. doi:10.14412/1995-4484-2020-304-316

45. Pope J, Sawant R, Tundia N, et al. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Adv Ther. 2020;37(5):2356-2372. doi: 10.1007/s12325-020-01303-3

46. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652-662. doi: 10.1056/NEJMoa1608345

47. Keystone EC, Taylor PC, Tanaka Y., et al. Patient-reported Outcomes From a Phase 3 Study of Baricitinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: Secondary Analyses From the RA-BEAM Study. Ann Rheum Dis. 2017;76(11):1853-1861. doi: 10.1136/annrheumdis-2017-211259

48. Taylor PC, Lee YC, Fleischmann R, et al. Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. J Clin Med. 2019;8(6). pii: E831. doi: 10.3390/jcm8060831

49. Smolen JS, Kremer JM, Gaich CL, et al. Patient-reported Outcomes From a Randomised Phase III Study of Baricitinib in Patients With Rheumatoid Arthritis and an Inadequate Response to Biological Agents (RA-BEACON). Ann Rheum Dis. 2017;76(4):694-700. doi: 10.1136/annrheumdis-2016-209821

50. Fautrel B, Zhu B, Taylor PC, et al. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison. RMD Open. 2020;6(1). pii: e001131. doi: 10.1136/rmdopen-2019-001131


Рецензия

Для цитирования:


Каратеев А.Е. Проблемы боли и качества жизни при ревматоидном артрите: фокус на барицитиниб. Научно-практическая ревматология. 2020;58(4):420-427. https://doi.org/10.47360/1995-4484-2020-420-427

For citation:


Karateev A.E. Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib. Rheumatology Science and Practice. 2020;58(4):420-427. (In Russ.) https://doi.org/10.47360/1995-4484-2020-420-427

Просмотров: 2185


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)